SAN MATEO, Calif., July 13, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced the pricing of its upsized initial public offering of 5,312,500 shares of its Series A common stock at a public offering price…Read More
Sagimet Biosciences Inc Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering
